Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. AWK
10. ACN

Go back to Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business

Ironwood Pharma (IRWD) Plans to Separate Could Unlock Value of Linzess Profit Stream - BTIG

May 1, 2018 1:48 PM EDT

BTIG analyst Timothy Chiang reiterated a Buy rating and $21 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) saying the company's plans to separate could unlock the value of Linzess profit stream.

Chiang commented, "Shares of IRWD opened down as much as ~9% this morning, but are now up ~4% following news that the Co. would look to split... More

Ironwood Pharma (IRWD) to Resume Trading at 8:30 am ET

May 1, 2018 8:20 AM EDT

Ironwood Pharma (NASDAQ: IRWD) to Resume Trading at 8:30 am ET

... More